ArticleCurrent treatment options in infectious diseases2017
Bone Loss in HIV Infection.
Article in Current treatment options in infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2019Guideline
- Administration of zoledronic acid alleviates osteoporosis in HIV patients by suppressing osteoclastogenesis via regulating RANKL expression.Molecular medicine (Cambridge, Mass.) · 2021Trial
- Antiretroviral Therapy-Induced Bone Loss Is Durably Suppressed by a Single Dose of Zoledronic Acid in Treatment-Naive Persons with Human Immunodeficiency Virus Infection: A Phase IIB Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Trial
- Improving osteoporosis prevention and care for patients with HIV: insights from HIV care providers in China.BMC health services research · 2025Article
- Bone health in a U.K. cohort of youth living with perinatally acquired HIV-1: a longitudinal study.Journal of the International AIDS Society · 2025Observational
- Evaluation of Bone Mineral Density and Related Factors in Romanian HIV-Positive Patients Undergoing Antiretroviral Therapy.Microorganisms · 2025Article
- β-Catenin: A Key Molecule in Osteoblast Differentiation.Biomolecules · 2025Review
- Narrative Review on the Management of Neck of Femur Fractures in People Living with HIV: Challenges, Complications, and Long-Term Outcomes.Microorganisms · 2025Review
- Evaluation of bone mineral density and its influencing factors in patients infected with HIV under antiretroviral therapy.BMC infectious diseases · 2025Article
- Cumulative incidence and treatment effectiveness of low bone mineral density among people living with HIV in Iran (2021-2023).AIDS research and therapy · 2024Article
- HIV Modulates Osteoblast Differentiation via Upregulation of RANKL and Vitronectin.Pathogens (Basel, Switzerland) · 2024Article
- Bone Metabolism in Men who Live with HIV Aged 50 years and Over: Impact of Infection Duration.Current HIV research · 2024Article
- Bone Health in People Living with HIV/AIDS: An Update of Where We Are and Potential Future Strategies.Microorganisms · 2023Review
- Massively HIV-1-infected macrophages exhibit a severely hampered ability to differentiate into osteoclasts.Frontiers in immunology · 2023Article
- The evaluation of risk factors related to reduced bone mineral density in young people living with HIV.African health sciences · 2022Article
- Does Aging Activate T-cells to Reduce Bone Mass and Quality?Current osteoporosis reports · 2022Review
- Bone Quality in Relation to HIV and Antiretroviral Drugs.Current HIV/AIDS reports · 2022Review
- Immune Reconstitution Bone Loss Exacerbates Bone Degeneration Due to Natural Aging in a Mouse Model.The Journal of infectious diseases · 2022Article
- Denosumab versus zoledronate for the treatment of low bone mineral density in male HIV-infected patients.Bone reports · 2021Article
- Changes in trabecular bone score and bone mineral density in Chinese HIV-Infected individuals after one year of antiretroviral therapy.Journal of orthopaedic translation · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Human immunodeficiency virus (HIV) infection is an established risk factor for low bone mineral density (BMD) and subsequent fracture, and treatment with combination antiretroviral therapy (cART) leads to additional BMD loss, particularly in the first 1-2 years of therapy. The prevalence of low BMD and fragility fracture is expected to increase as the HIV-infected population ages with successful treatment with cART. Mechanisms of bone loss in the setting of HIV infection are likely multifactorial, and include viral, host, and immune effects, as well as direct and indirect effects of cART, particularly tenofovir disoproxil fumarate (TDF) and the protease inhibitors (PIs). Emerging data indicate that BMD loss following cART initiation can be mitigated by prophylaxis with either long-acting bisphosphonates or vitamin D and calcium supplementation. In addition, newer antiretrovirals, particularly the integrase strand transfer inhibitors and tenofovir alafenamide (TAF), are associated with less intense bone loss than PIs and TDF. However, further studies are needed to establish optimal bone sparing cART regimens, appropriate screening intervals, and preventive measures to address the rising prevalence of fragility bone disease in the HIV population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.